FDA approves daraxonrasib for patients with metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment. This marks a significant development for a disease with historically limited treatment options and poor survival rates.

Experts at Moores Cancer Center at UC San Diego Health are available to discuss what this approval means for patients, how the therapy fits into current treatment approaches, and ongoing efforts to improve outcomes through precision medicine, clinical trials and earlier detection.

Available experts

Gregory Botta, MD, PhD, medical oncologist at UC San Diego Health and associate professor of medicine at University of California San Diego School of Medicine

Available to discuss:

• Significance of the FDA approval for patients with metastatic pancreatic cancer
• How daraxonrasib works and which patients may benefit
• Treatment options after standard therapies stop working T
• he evolving landscape of targeted therapies in pancreatic cancer Clinical trial research and future directions in KRAS-targeted cancer treatment

Diane Simeone, MD, director at Moores Cancer Center at UC San Diego Health and founder and chief scientific advisor at Pancreatic Cancer Early Detection Consortium (PRECEDE)

Available to discuss:

• What this approval means for the future of pancreatic cancer treatment
• The importance of combining treatment advances with earlier detection efforts
• New research aimed at improving survival and quality of life National efforts to identify pancreatic cancer earlier and more accurately

Key facts

• Pancreatic cancer is one of the leading causes of cancer-related death in the U.S. and has among the lowest five-year survival rates of all major cancers.
• Moores Cancer Center at UC San Diego Health, the region's only National Cancer Institute-designated Comprehensive Cancer Center, contributed to both the clinical research that supported daraxonrasib's development and early patient access through the Expanded Access Program, helping bring the therapy to patients before its FDA approval.
• As the only academic medical center in the region, UC San Diego Health researchers continue to lead clinical trials and translational research focused on pancreatic cancer and other difficult-to-treat cancers.
• For more information on pancreatic cancer care, please visit health.ucsd.edu/care/cancer/cancers-we-treat/pancreatic.